Financial Data and Key Metrics Changes - Total revenue for Q3 2021 was $19.7 million, which included $18.3 million from the RHA Collection, $1.1 million from the partnership with Viatris on the biosimilar to BOTOX, and $0.3 million from the fintech platform [33] - Selling, general and administrative expenses for Q3 were $52.8 million, with non-GAAP SG&A expenses at $45.1 million [34] - Research and development expenses were $30.1 million for Q3, with non-GAAP R&D expenses at $25.7 million [35] - Cash, cash equivalents, and short-term investments as of September 30, 2021, were $273.7 million [36] Business Line Data and Key Metrics Changes - RHA revenue for Q3 was $18.3 million, a 7.4% increase over Q2, driven by higher sales from existing accounts and the addition of new accounts [21] - The RHA Collection has been positioned as the most natural and least modified hyaluronic acid dermal filler on the market, with over 2,500 aesthetic accounts established [22] - OPUL maintained a payment processing volume run rate of over $0.5 billion despite a traditionally slower season [25] Market Data and Key Metrics Changes - The muscle movement disorder market opportunity currently stands at $1.2 billion worldwide, with approximately 78% of that opportunity in the U.S. [12] - The overall market for facial injectables remains robust, with expectations for a seasonally strong Q4 heading into the holiday season [21][61] Company Strategy and Development Direction - The top strategic priority is to obtain FDA approval for DaxibotulinumtoxinA for Injection for glabellar lines as soon as possible [14] - The company aims to increase revenue in the $1.2 billion U.S. dermal filler market with the RHA Collection and expand customer relationships through OPUL [14] - Organizational changes were announced to streamline operations and enhance performance, including the promotion of Dustin Sjuts to President [16] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment regarding the CRL received from the FDA but remains determined to achieve product approval [7][9] - The company believes the deficiencies cited in the CRL were limited to manufacturing facility observations and not related to clinical data [13] - Management is focused on preserving cash to enhance financial flexibility while continuing to build the business long-term [41] Other Important Information - The company plans to provide updated cash guidance following the Type A meeting with the FDA [40] - The ASPEN-OLS study for cervical dystonia demonstrated that DaxibotulinumtoxinA for Injection was generally safe and well-tolerated [28] Q&A Session Summary Question: Clarity on the CRL and consulting efforts - Management indicated that the Establishment Inspection Report provided additional clarity and comfort regarding the responses to the FDA [46] - The company continues to leverage external experts to navigate the approval process [49] Question: Impact of the pandemic on FDA inspection timing - Management stated that it is speculative to comment on pandemic-related issues affecting timing, with clarity expected after the Type A meeting [55] Question: Trajectory for RHA fillers and account expansion - Management expressed confidence in the ongoing growth of RHA and the potential to increase account penetration, despite the absence of DaxibotulinumtoxinA [61][63] Question: Update on the partnership with TEOXANE - The relationship with TEOXANE remains strong, with no adverse impacts from the stock performance related to the CRL [100]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or o ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercial Officer, Aesthetics and Therapeutics Aubrey Rankin - President, Innovation and Technology Conference Call Participants Seamus Fernandez - Guggenheim Terence Flynn - Goldman Sachs Annabel Samimy - Stifel David Ams ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2021 Results Conference Call May 10, 2021 4:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercial Officer, Aesthetics and Therapeutics Aubrey Rankin - President, Innovation and Technology Conference Call Participants Ken Cacciatore - Cowen & Company Seamus Fernandez - Guggenheim Terence Flynn - Goldman Sachs Ann ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ( Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (I.R.S. Employer Id ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2020 Earnings Conference Call February 22, 2021 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations and ESG Mark Foley - President and Chief Executive Officer Toby Schilke - Chief Financial Officer Roman Rubio - Senior Vice President Clinical Development Dustin Sjuts - Chief Commercial Officer, Therapeutics & Aesthetics Abhay Joshi - Chief Operating Officer and President of R&D and Product Operation Conference Call Participants Ken Cacciator ...

| --- | --- | --- | |---------------------------------------------------------|-------|-------| | | | | | | | | | Daring To Make A Difference Daring To Make A Difference | | | | COMPANY PRESENTATION NOVEMBER 2020 | | | Forward-Looking Statements Safe Harbor / Market Data 2 This presentation contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the market ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Jeanie Herbert - Head of Investor Relations Mark Foley - President & Chief Executive Officer Toby Schilke - Chief Financial Officer Dustin Sjuts - Chief Commercial Officer, Therapeutics & Aesthetics Conference Call Participants Ken Cacciatore - Cowen & Company Annabel Samimy - Stifel Terence Flynn - Goldman Sachs David Amsellem - Piper Sandler Kush Patel - Guggenheim Tim Lugo - William ...